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MaArrhythmia-induced cardiomyopathy (AIC) is a potentially reversible condition in which left ventricular dysfunction is
induced or mediated by atrial or ventricular arrhythmias. Cellular and extracellular changes in response to the culprit
arrhythmia have been identiﬁed, but speciﬁc pathophysiological mechanisms remain unclear. Early recognition of AIC and
prompt treatment of the culprit arrhythmia using pharmacological or ablative techniques result in symptom resolution
and recovery of ventricular function. Although cardiomyopathy in response to an arrhythmia may take months to years to
develop, recurrent arrhythmia can result in rapid decline in ventricular function with development of heart failure,
suggesting residual ultrastructural abnormalities. Reports of sudden death in patients with normalized left ventricular
ejection fraction cast doubt on the complete reversibility of this condition. Several aspects of AIC, including speciﬁc
pathophysiological mechanisms, predisposing factors, optimal therapeutic strategies to prevent ultrastructural changes,
and long-term risk of sudden death remain unresolved and need further research. (J Am Coll Cardiol 2015;66:1714–28)
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AB BR E V I A T I O N S
AND ACRONYM S
AET = atrial ectopic
tachycardia
AF = atrial ﬁbrillation
AIC = arrhythmia-induced
cardiomyopathy
AT = atrial tachycardia
AV = atrioventricular
BNP = B-type natriuretic
peptide
HF = heart failure
JET = junctional ectopic
tachycardia
LV = left ventricle/ventricular
LVEF = left ventricular
ejection fraction
NT-proBNP = N-terminal
pro-B-type natriuretic peptide
PJRT = permanent junctional
reciprocating tachycardia
PVC = premature ventricular
complex
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AIC is a condition in which atrial or ventricular
tachyarrhythmias or frequent ventricular ectopy re-
sult in left ventricular (LV) dysfunction, leading to
systolic HF (1,2). The hallmark of this condition is
partial or complete reversibility once arrhythmia
control is achieved. AIC can be classiﬁed into 2 cate-
gories: one in which arrhythmia is the sole reason for
ventricular dysfunction (arrhythmia induced) and
another in which the arrhythmia exacerbates ventric-
ular dysfunction and/or worsens HF in a patient with
concomitant heart disease (arrhythmia mediated) (3).
EPIDEMIOLOGY
The incidence and prevalence of AIC are uncertain,
but AIC appears underrecognized. Atrial ﬁbrillation
(AF) is present in 10% to 50% of patients with HF;
many patients with cardiomyopathy and AF have
worsening symptoms and ventricular function solely
due to poorly controlled ventricular rates (4). In 2
studies of adult patients with focal atrial tachycardia
(AT), the incidence of AIC was 8.3% to 10% (5,6),
whereas 28% had AIC in a pediatric multicenter study
of atrial ectopic tachycardia (AET) (7). The incidence
of AIC was 9% to 34% in patients with frequent pre-
mature ventricular complexes (PVCs) and/or non-
sustained ventricular tachycardia referred for
electrophysiological evaluation (8–10).
PATHOPHYSIOLOGY, MECHANISMS, AND
PREDISPOSING FACTORS
PATHOPHYSIOLOGY: INSIGHTS FROM ANIMAL
MODELS. Chronic rapid pacing has long been recog-
nized to cause HF in animal models (11). LV remod-
eling and HF occur in a time-dependent and highly
predictable manner, similar to the phenotype of AIC
(12–18). Due to the rapidly progressive and predict-
able nature of pacing to induce cardiomyopathy, the
natural history of LV remodeling and failure, neuro-
hormonal activation and signaling, and cell viability
and molecular pathways have been examined in
detail. The Central Illustration shows the natural his-
tory and contributing cellular and molecular events in
rapid pacing–induced cardiomyopathy and HF.
LV REMODELING AND HF. During the early phase
(the ﬁrst 3 to 7 days) of rapid pacing, LV dilation
occurs, with a decline in LVEF (12–15). This early
remodeling phase is not accompanied by compro-
mises in cardiac output or systemic perfusion pres-
sures. By the second week, LV dilation, a fall in LVEF,
and elevations in central venous and pulmonarycapillary wedge pressures and systemic
vascular resistance ensue (12–17). Eventually
HF develops.
Whereas initial manifestations are adap-
tive, sustained rapid pacing affects LV
load-ejection relationships, speciﬁcally, the
pre-load recruitable LV stroke–work relation-
ship (17), the LV systolic wall stress–ejection
relationship, and the slope of the LV end-
systolic pressure–volume relationship (18).
LV dilation and dysfunction are accompanied
by a decline in intrinsic myocardial contractile
function.
NEUROHORMONAL ACTIVATION. Rapid pacing
in animals results in a predictable, time-
dependent change in neurohormonal path-
ways and synthesis and release of bioactive
peptides (19–25). The levels of plasma atrial
natriuretic peptide and B-type natriuretic
peptide (BNP) increase early, concomitant
with LV dilation (19,21); eventually natri-
uretic peptide levels plateau or decrease,
likely due to suppression of synthesis and
increased degradation by endopeptidases. Another
hallmark is activation of sympathetic pathways,
resulting in norepinephrine spillover (20,21). Consis-
tent with the phenotype of progressive LV failure,
rapid pacing invariably causes activation of the
renin-angiotensin-aldosterone system (20,25). Other
bioactive molecules activated and released include
endothelin and inﬂammatory cytokines such as
tumor necrosis factor alpha (24).
Whereasmediators of vasoconstriction are induced,
mediators of vasodilation, such as the response to
nitric oxide, become impaired (22,23). Several key
aspects regarding these temporal changes in the
neurohormonal/bioactive signaling pathways hold
relevance. First, shifts in key neurohormonal path-
ways, such as the natriuretic peptides and the renin-
angiotensin-aldosterone system, likely reﬂect shifts
in underlying LV functional status from a “compen-
sated” to a “decompensated” state. Thus, neurohor-
monal measurements may serve as useful biomarkers
for the progressive nature/status of AIC. Secondly, it is
likely that stimulation of key pathways, such as the
adrenergic and cytokine systems, contribute directly
to myocardial dysfunction.
CELL SIGNALING AND VIABILITY. Under normal
conditions, increased contraction frequency causes
a progressive rise in myocardial contractile perfor-
mance due to appropriate changes in Ca2þ handling
and in the myoﬁlament response to Ca2þ. However,
this positive force–frequency relationship is blunted
CENTRAL ILLUSTRATION Schematic Illustration of the Natural History and Pathophysiology of Rapid Pacing–Induced
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In response to rapid pacing in animals, left ventricular (LV) remodeling and heart failure occur in a time-dependent and highly predictable manner, similar to the
phenotype of arrhythmia-induced cardiomyopathy. Several cellular and molecular events in response to the initial tachyarrhythmia stimulus take place over a period of
approximately 3 to 4 weeks and involve both extracellular matrix (ECM) and myocyte remodeling. Speciﬁcally, there is loss of normal extracellular matrix and
architecture. This, coupled with alterations in cellular growth and viability, defects in Ca2þ handling, and neurohormonal activation, results in LV dilation and severe
contractile dysfunction. The natural history of rapid pacing–induced cardiomyopathy progresses from a compensatory phase (approximately >7 days) to an LV
dysfunction phase (approximately 1 to 3 weeks) to an LV failure phase (approximately >3 weeks), characterized by progressive LV dilation and dysfunction and
increasing neurohormonal activation. ATPase ¼ adenosine triphosphatase; RAAS ¼ renin-angiotensin-aldosterone system.
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1716with pacing-induced cardiomyopathy (26), with
accompanied prolongation of myocardial Ca2þ tran-
sients and defects in Ca2þ cycling (27). These changes
in the force-frequency relation and Ca2þ handling are
a manifestation of prolonged rapid pacing and are
present when deﬁnable changes in LV systolic func-
tion have already occurred (27–30). The summation of
changes in Ca2þ handling results in fundamental de-
fects in the excitation-contraction coupling process,
leading to defects in absolute myocyte contractile
function and inotropic responsiveness (27–30).In isolated myocyte preparations, intrinsic defects
in the rate and extent of shortening, as well as defects
in the rate of relaxation, have been identiﬁed as car-
diomyopathy develops and progresses (20,28,31).
Changes in cellular growth and viability ensue (32,33).
Chronic rapid pacing induces several proapoptotic
cascades (34). LV dilation is not associated with an
absolute increase in myocyte cross-sectional area but
rather with lengthening of individual myocytes, with
alterations in cytoskeletal architecture (20,29,31,35).
If these changes in myocyte function and viability
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1717were placed in a temporal context, then LV myocyte
remodeling (cell shape and architecture) is likely to
occur early, followed by abnormalities in excitation-
contraction and changes in cell viability.
EXTRACELLULAR REMODELING. Although remodel-
ing occurs within the myocyte, robust changes also
occur within the extracellular matrix (35,36). Specif-
ically, there is a loss of normal ﬁbrillar collagen con-
tent and distribution (35,36), which, in turn, initiates
alterations in myocyte support and alignment within
the LV wall. Concomitantly, the capacity of myocytes
to bind to the extracellular matrix is diminished (35),
suggesting that abnormalities in the extracellular
matrix–integrin interface have occurred. Increased
matrix metalloproteinase activity and expression
contribute to loss of normal extracellular matrix
support and architecture (37). Activation of matrix
metalloproteinases precedes the defects in myocyte
contractile function (37). These ﬁndings suggest that
the likely mechanism for LV remodeling is loss of
normal myocardial extracellular matrix structure,
composition, and function.
IMPLICATIONS OF ANIMAL STUDIES. Chronic rapid
pacing in animals causes dilated cardiomyopathy
resembling clinical AIC. With rapid atrial pacing in
pigs, an atrioventricular (AV) conduction pattern is
maintained and ventricular dyssynchrony as the
stimulus for adverse remodeling and HF is unlikely
(12,13,20). However, rapid ventricular pacing, where
myocardial dyssynchrony is inevitable, results in a
more rapid and precipitous fall in LV systolic perfor-
mance (14–17). Thus, the tachycardia stimulus is suf-
ﬁcient to drive the cardiomyopathy process, whereby
electrical dyssynchrony would constitute an additive
factor accelerating the process.
Phases and structural milestones that occur with
chronic arrhythmias in animal models translate to
clinical forms of AIC. Speciﬁcally, there is an adaptive/
compensatory phase whereby LV dilation, extracel-
lular matrix remodeling, and neurohormonal system
activation occurs but severe LV dysfunction does not.
This phase could be identiﬁed in patients by LV imag-
ing and biomarker proﬁling and is followed by a phase
in which LV dysfunction becomes manifest and asso-
ciated with defects in excitation-contraction coupling
and LV myocyte remodeling and dysfunction. This
phase likely represents a critical transition when this
process may not completely reverse, leading to
neurohormonal activation accompanied by the full
pathophysiological spectrum of HF.
Several challenges and limitations exist in trans-
lating animal data to humans. The time course
for development of AIC and HF in patients withotherwise structurally normal hearts is usually
months to years, which is quite different from the
acute changes seen in pacing models. Some ar-
rhythmias (e.g., AF and PVCs) may have mecha-
nisms leading to AIC that are not explained fully
by rapid-pacing animal models (10,38–40). Although
ultrastructural changes may explain the initial de-
velopment of AIC, the relationship between identiﬁ-
able ultrastructural changes and the mechanisms by
which cardiomyopathy develops are less clear. An
overview of the current understanding of the rela-
tionship between arrhythmias and cardiomyopathy,
from mechanisms to management and prognosis, is
shown in Figure 1.
ARRHYTHMIA AND PATIENT CHARACTERISTICS. Ar-
rhythmia characteristics contributing to AIC include
arrhythmia type (Table 1), rate, duration, rhythm ir-
regularity, persistence (5,41–43), and concomitant
heart disease (44). An arrhythmia that is insidious,
persistent, and well tolerated is more likely to result
in AIC (5). Lack of persistent tachycardia from auto-
nomic inﬂuences and resultant slower rates during
sleep are likely to be the reasons that AIC is rare or
nonexistent with inappropriate sinus tachycardia and
postural orthostatic tachycardia syndrome (POTS),
although the average heart rate can be >100 beats/
min. There is no speciﬁc heart rate cutoff at which AIC
develops. The rate is not well deﬁned, may be age
dependent, and is likely lower than initially sus-
pected. Little is known about patient factors that
increase vulnerability to AIC, but one report has
indicated that patients with a homozygous deletion
polymorphism in the angiotensin-converting enzyme
(DD) gene had a higher propensity to develop AIC
when faced with persistent tachycardia, suggesting a
potential genetic link (45). In a longitudinal study of
patients with high PVC burden, those who developed
cardiomyopathy had wider PVC QRS width versus
those who did not, suggesting baseline myocardial
ﬁber disruption that portends an increased risk (46).
CLINICAL FEATURES AND DIAGNOSIS
The key diagnostic feature of AIC is the presence of a
pathological tachycardia or persistent arrhythmia
(PVC) in the presence of an otherwise unexplained
cardiomyopathy. The relationship of arrhythmia to
cardiomyopathy can be difﬁcult to determine be-
cause an arrhythmia could exist for years before its
recognition and before cardiomyopathy develops.
Although a high index of clinical suspicion may point
to subtle diagnostic clues, the condition may go un-
recognized for years. The presentation can be late
only after manifest systolic HF develops. Similarly, if
FIGURE 1 Overview of the Current Understanding of AIC, From Mechanisms to Management and Prognosis
Persistent tachyarrhythmia or frequent ventricular ectopy (PVC)
No known structural heart disease Underlying structural heart disease
Patient and arrhythmia characteristics
– Adverse cellular, cytoskeletal, neurohormonal, and proapoptotic changes
(see Central Illustration)
– Other mechanisms (ventricular dyssynchrony, abnormal Ca2+ handling, etc.)
Development of left ventricular (LV) dysfunction,
dilated cardiomyopathy, and heart failure —
arrhythmia–induced cardiomyopathy (AIC)
– Suppression/elimination of arrhythmia by rate
   and/or rhythm control
– Heart failure therapy
– Heart failure resolution and LV function recovery
– Confirms diagnosis of AIC
No significant improvement in LV function —
Not AIC
Follow up:
1.    Maintain sinus rhythm/strict rate
       control
2.    Close surveillance to avoid arrhythmia
        recurrence
3.    Continue beta–blockers/ACE inhibitors
4.    Follow–up imaging (echo and/or MRI)
No evidence of persistent ultra–structural changes
by echo or cardiac MRI
Persistent ultra–structural changes:
1.         LV dimensions
2.     Evidence for fibrotic changes in MRI
3.     Development of LV hypertrophy
Good prognosis
– Close surveillance
– Continue beta–
   blockers/ACE inhibitors
Persistent tachyarrhythmias or frequent ventricular ectopy can lead to dilated cardiomyopathy and decompensated heart failure in patients with or without
concomitant structural heart disease. Cellular and extracellular changes in response to the culprit arrhythmia have been identiﬁed (see Central Illustration),
but speciﬁc pathophysiological mechanisms have not been well elucidated. Early recognition of the relationship of a culprit arrhythmia to cardiomyopathy
and aggressive arrhythmia control results in improved symptoms, left ventricular (LV) ejection fraction, and functional status and helps establish the
diagnosis of arrhythmia-induced cardiomyopathy (AIC). Cellular and extracellular ultrastructural changes can, however, persist and can contribute to a rapid
decline in cardiac function with arrhythmia recurrence. Close surveillance is thus crucial to ensure good long-term prognosis. ACE ¼ angiotensin-converting
enzyme; MRI ¼ magnetic resonance imaging; PVC ¼ premature ventricular complex.
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1718the arrhythmia is detected early but a nonaggressive
approach is taken, progressive worsening of symp-
toms and insidious development of cardiomyopathy
ensue. It can be difﬁcult to determine whether an
arrhythmia is the initiator or consequence of car-
diomyopathy in a patient with tachycardia and HF.
Thus, AIC raises a “chicken or egg” question (47).
Frequently, the arrhythmia is considered secondary
and is not treated effectively when, in fact, arrhythmia
control is necessary for full recovery.
History, physical examination, and clinical in-
vestigations should focus on determining the etiology
of cardiomyopathy. Speciﬁc patient characteristics
may suggest a higher likelihood of AIC. Patients with
AIC have a smaller LV end-diastolic diameter andmass index versus those with pre-existing dilated
cardiomyopathy and concomitant tachyarrhythmia
(48,49). Cardiac magnetic resonance imaging (CMR)
may help differentiate AIC from dilated cardiomyop-
athy. In a study of 27 patients with frequent PVCs
and cardiomyopathy, 22 had improvement in LVEF
following PVC suppression; 5 did not. Four of the
5 patients with LVEF that did not improve had evi-
dence for late gadolinium enhancement, suggesting
underlying scar (8). Campos et al. (49) compared
patients with irreversible nonischemic dilated car-
diomyopathy, reversible PVC-mediated cardiomyo-
pathy, and patients with PVCs and normal LVEF
who underwent electroanatomic mapping. These
investigators noted that those with irreversible
TABLE 1 Causes of Arrhythmia-Induced Cardiomyopathy
Supraventricular
Atrial ﬁbrillation
Atrial ﬂutter
Atrial tachycardia
AV nodal re-entrant tachycardia
AV re-entrant tachycardia
Permanent junctional reciprocating tachycardia
Junctional ectopic tachycardia
Ventricular
Idiopathic ventricular tachycardia
Fascicular tachycardia
Ectopy
Frequent premature ventricular contractions
Frequent premature atrial contractions
Pacing
Persistent rapid atrial and/or ventricular pacing
Adapted with permission from Gopinathannair et al. (2).
AV ¼ atrioventricular.
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1719cardiomyopathy had a signiﬁcantly larger percentage
of the LV endocardium with abnormal unipolar
voltage (64% vs. 5.2% for the reversible group and
0.1% for the normal LVEF group). An abnormal uni-
polar voltage area $32% of LV endocardium predicted
the irreversibility of cardiomyopathy with >95%
sensitivity and speciﬁcity, but prospective validation
is lacking (49).
Serial assessment of the N-terminal pro-BNP
(NT-proBNP) ratio (NT-proBNP at baseline/NT-
proBNP during follow-up) can differentiate AIC from
irreversible dilated cardiomyopathy. Forty patients
with AF or atrial ﬂutter with ventricular rates >100
beats/min and LVEF <40% were cardioverted, and
NT-proBNP was measured on day 1 and weekly for
4 weeks. An NT-proBNP ratio cutoff >2.3 at 1 week,
suggesting rapid decline in NT-proBNP levels, was
associated with reversible cardiomyopathy, with an
accuracy of 90% (50).
When AIC cannot be easily differentiated from
dilated cardiomyopathy with consequent tachy-
cardia, treatment for both problems becomes neces-
sary (2). The diagnosis may be evident only after
restoration and maintenance of sinus rhythm or after
aggressive rate control.
PRINCIPLES OF MANAGEMENT
AIC management should focus on concerted attempts
to eliminate or control the arrhythmia, with the goal
of improving symptoms, reversing LV dysfunction,
and preventing arrhythmia recurrence (1,5,43,51,52).
A favorable response to arrhythmia elimination/
control establishes the diagnosis of AIC. Along witharrhythmia control, use of neurohormonal antago-
nists can result in favorable ventricular remodeling.
Controversy remains about the need to continue
these medications if there is complete recovery of
LVEF with arrhythmia control.
AIC ASSOCIATED WITH SPECIFIC
ARRHYTHMIAS IN ADULTS
ATRIAL FIBRILLATION. AF is the most common
cause of AIC in adults (1,43). Of patients presenting
with HF, 10% to 50% have AF (4,53), and many such
patients likely have a component of AIC. The mech-
anisms underlying development or progression of
cardiomyopathy in patients with persistent AF have
not been elucidated clearly (39). Rapid heart rates,
loss of atrial contraction, and rhythm irregularity may
contribute (1,39,40,54). Persistent tachycardia can
impair myocardial contractility, either directly or
through alterations in cellular and neurohormonal
mechanisms. Resting tachycardia, as well as a rapid
increase in heart rate with exercise, can impair dia-
stolic ﬁlling. Lack of atrial contribution to ventricular
ﬁlling can further worsen diastolic function. A vicious
cycle can thus develop, with HF and associated in-
creases in left-sided ﬁlling pressures and functional
mitral regurgitation resulting in mechanoelectrical
changes in the left atrium, perpetuating AF and car-
diomyopathy (54).
Management of AF consists of rate and/or rhythm
control. In those with AF and cardiomyopathy, the
ideal target heart rate remains uncertain. For those
with permanent AF, lenient rate control (resting heart
rate <110 beats/min) has been advocated over strict
rate control (resting heart rate <80 beats/min and
heart rate with moderate exercise <110 beats/min)
(55). However, in the RACE II (Rate Control Efﬁcacy in
Permanent Atrial Fibrillation II) trial (55), most pa-
tients were rate controlled before enrollment (base-
line heart rate 96 beats/min) and were asymptomatic
without cardiomyopathy. Follow-up was short, and
development of AIC was not speciﬁcally considered.
Several methods are available for AF rate control
(56). Achieving adequate rate control may require
drug combinations and frequent regimen changes
(57). However, these data may not directly apply
to AF-mediated AIC because rate irregularity may
contribute to symptoms and facilitate development of
AIC (40). Although AV nodal ablation with pacemaker
implantation can provide effective rate control (58)
and regularize the rate, this strategy changes ven-
tricular activation, even if cardiac resynchronization
therapy is used; therefore, it should only be con-
sidered if rhythm and/or rate control cannot be
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1720established. In contrast, electrical or pharmacological
cardioversion, antiarrhythmic drugs, and catheter
ablation can achieve rhythm control. In AF-mediated
cardiomyopathy, restoration and maintenance of si-
nus rhythm can hasten clinical recovery and reverse
cardiomyopathy over several months (1,40,59).
The AF-CHF (Atrial Fibrillation and Congestive
Heart Failure) trial randomized 1,376 patients with AF
(70% persistent) and HF to either a rhythm control
(amiodarone with cardioversion) or a rate control
strategy. The mean LVEF was 27% and patients were
followed for 37 months. A rhythm control strategy
using antiarrhythmic drugs did not improve all-cause
mortality or prevent worsening HF. However, the AF-
CHF patient population may not fully represent the
AIC population because 40% of patients in the rate
control arm were in sinus rhythm during follow-up
(60). The CAFÉ-II (Controlled Study of Rate Versus
Rhythm Control in Patients With Chronic AF and
Heart Failure) study randomized 61 patients with
persistent AF (median duration of 14 months) and
moderate LV dysfunction to a rate control and
rhythm control strategy (amiodarone with cardio-
version). During a follow-up of 1.2 years, 66% of
patients maintained sinus rhythm, whereas 90%
achieved target rate control (<80 beats/min at rest
and <110 beats/min with 6-min walk). Rhythm con-
trol was superior to rate control in improving LV
function, pro-BNP levels, and quality of life (61). At-
tempts to control rate might not be as aggressive or
carefully monitored in the real world as in clinical
trials. It is also possible that side effects and proar-
rhythmic risks from antiarrhythmic drugs may offset
any salutary effects from restoring and maintaining
sinus rhythm (62).
Restoring and maintaining sinus rhythm by cath-
eter ablation of AF can improve and reverse AIC
(63,64). Pulmonary vein isolation appears superior to
AV node ablation and biventricular pacing in patients
with drug-refractory AF and HF (64). A systematic
review of 19 studies (n ¼ 914) evaluating AF ablation
in patients with concomitant LV dysfunction showed
that sinus rhythm was maintained in 57% after
a single procedure, with an increase to 82% with
>1 procedure and/or use of antiarrhythmic drugs (65).
LVEF increased by 13.3% (95% CI: 11% to 16%), sug-
gesting the effectiveness of catheter ablation for
maintaining sinus rhythm and reversing AIC.
The recent AATAC-AF (Ablation vs. Amiodarone
for Treatment of Atrial Fibrillation in Patients With
Congestive Heart Failure and an Implanted ICD/CRTD)
trial randomized 203 patients with persistent AF
with HF and cardiomyopathy (LVEF <40%) to either
amiodarone or catheter ablation. During a 24-monthfollow-up, 70% of patients in the ablation arm were
free of AT/AF (vs. 34% in the amiodarone arm
[p < 0.001]) and had signiﬁcant improvements in
mortality, hospitalization rates, and quality of life.
LVEF improved 9.6  7.4% in the ablation arm versus
4.2  6.2% in the amiodarone arm (p < 0.01) (66).
Catheter ablation thus offers an effective rhythm
control strategy and avoids potentially toxic long-term
antiarrhythmic therapy. The available data argue for
catheter ablation as the best choice for rhythm control
in patients with AF-mediated AIC.
ATRIAL FLUTTER. Atrial ﬂutter is more difﬁcult to
rate control than AF, given less concealed conduction
into the AV node. Therefore, despite intense efforts at
pharmacological rate control, minimal exertion can
lead to rapid ventricular rates. Given the inherent
difﬁculty with rate control and the high success rate
and low risk of complications with catheter ablation
(67,68), ablation to eliminate atrial ﬂutter is recom-
mended when AIC is suspected. For those in whom
catheter ablation is not feasible or desired, cardio-
version with antiarrhythmic therapy or aggressive
rate control should be used.
SUPRAVENTRICULAR TACHYCARDIAS. Persistent sup-
raventricular tachycardias can result in AIC by several
mechanisms (5). Near simultaneous AV relationships
can have a negative hemodynamic effect. A curative
strategy by catheter ablation should be pursued
whenever possible as ﬁrst-line therapy for supra-
ventricular tachycardia-mediated AIC. Successful
catheter ablation can normalize LVEF and is usually
associated with excellent long-term outcomes (5,6).
PVCs AND VENTRICULAR TACHYCARDIA. Idiopathic
ventricular tachycardia and, more commonly, fre-
quent PVCs can lead to AIC in patients without
structural heart disease and can exacerbate car-
diomyopathy in patients with structural disease
(10,52,69,70). PVCs associated with cardiomyopathy
usually arise in the right or left ventricular outﬂow
tract, but PVCs from non–outﬂow tract sites can also
result in AIC (10,46,52).
The mechanism of PVC-mediated AIC is not fully
understood. A large animal model using a pacing
protocol to simulate paroxysmal PVCs produced an
AIC phenotype that resolved completely within 2 to 4
weeks after pacing cessation. Tissue analysis did not
show evidence of inﬂammation, ﬁbrosis, or apoptosis,
suggesting that PVC-induced cardiomyopathy in
structurally normal hearts could be a functional ab-
normality (38). Potential mechanisms postulated
include ventricular dyssynchrony, especially related
to a left bundle branch block PVC morphology,
abnormal Ca2þ handling from the short coupling
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post-PVC pause (10,37,38).
The development of cardiomyopathy with atrial
premature depolarizations (71) and the absence of
convincing site-speciﬁc association in PVC-mediated
AIC suggest that it may not be a simple matter of LV
dyssynchrony. The causal relationship between PVCs
and AIC has been ﬁrmly established on the basis of
reversal of the cardiomyopathy with suppression
and/or elimination of PVCs (72,73).
The most prominent predictor of cardiomyopathy
in patients with frequent PVCs appears to be the
daily burden of PVCs. A high PVC burden has been
variably deﬁned as ranging from >10,000 to 25,000
PVCs/day and as >10% to 24% of total heartbeats/
day (74–76). There appears to be a threshold burden
of approximately 10,000 PVCs/day for developing
AIC. Ventricular function can improve if the PVC
burden is reduced to <5,000/day (72). This is an
important target when elimination of all PVCs may
not be possible, especially in the setting of multi-
form PVCs.
Retrospective studies suggest multiple potential
patient and PVC characteristics associated with the
development of AIC (9,10,74,77,78). These character-
istics include male sex, increased body mass index,
asymptomatic PVCs, higher PVC coupling interval
dispersion, interpolated PVCs, and presence of
retrograde P waves (10,77–80). In a study of patients
with high PVC burden followed for 14 months, 17
(38%) developed AIC. A PVC QRS duration >153 ms
and non–outﬂow tract origin predicted development
of AIC (46). Importantly, most patients with frequent
PVCs will not develop cardiomyopathy (76). Cur-
rently, although an important goal of future investi-
gation, no risk proﬁle deﬁnes a group of patients
requiring prophylactic PVC elimination to prevent
AIC. However, it is advisable for patients with a
high PVC burden to have periodic echocardiographic
assessments to conﬁrm stable LV chamber size and
function.
Therapy for PVC-mediated AIC should be targeted
at suppressing or eliminating the PVCs and should
include antiarrhythmic therapy and catheter abla-
tion. Beta-blockade and non–dihydropyridine cal-
cium channel blockade are low-risk therapies, but
they have limited effectiveness. Beta-blockers are
frequently considered ﬁrst-line treatment because of
the benign nature of the treatment. Dofetilide, mex-
iletine, sotalol, or amiodarone may be more effective,
although they have greater risk of side effects and
proarrhythmia. Antiarrhythmic drug use is frequently
reserved for patients who fail or are reluctant to un-
dergo catheter ablation.Catheter ablation has emerged as the deﬁnitive
therapy for PVC-mediated AIC, with success rates
ranging from 70% to 90% (52). Elimination of PVCs
with ablation has been shown to improve LVEF,
ventricular dimensions, mitral regurgitation, and
functional status. In an observational series, ablation
was superior to antiarrhythmic therapy in reducing
PVCs and improving LVEF (51). Successful ablation of
PVCs can improve the efﬁcacy of cardiac resynchro-
nization therapy in nonresponders (81). The elimi-
nation of high PVC burden (>10%) in patients with
impaired LVEF can be associated with improvement
of function, even when structural cardiac abnormal-
ities are present (72,73,82).
MANAGEMENT IN ADULTS—SUMMARY. Our approach
to manage patients with suspected AIC is to attempt
careful and aggressive control of rate and rhythm,
with the focus on arrhythmia elimination by cath-
eter ablation whenever possible. The only tachyar-
rhythmias that do not appear to require aggressive
treatment to prevent AIC are sinus tachycardia and
POTS. Continued therapy with neurohormonal an-
tagonists is advisable for favorable remodeling, al-
though the duration of such therapy is not well
deﬁned (83).
AIC IN CHILDREN
In children, dilated cardiomyopathy is the most
common reason for heart transplant (84). Nearly
40% of children with cardiomyopathy undergo heart
transplant or die within 2 years of presentation (85).
AIC must be considered in this setting. In the largest
pediatric series of AIC, AET (59%) and permanent
junctional reciprocating tachycardia (PJRT; 23%) were
the most common arrhythmias represented. Ventric-
ular arrhythmias were uncommon (86).
Tachyarrhythmias are a reversible cause of car-
diomyopathy from fetal life onward (87–90). Children
often present late because they fail to recognize pal-
pitations or are unable to verbalize symptoms and
come to medical attention only after the development
of HF. Compared with adults, different arrhythmia
mechanisms are represented in pediatric AIC.
Supraventricular arrhythmias are more common
than ventricular arrhythmias in children and there-
fore are more frequently associated with AIC. In the
newborn, a single, sustained episode of typical sup-
raventricular tachycardia may be unrecognized until
HF symptoms emerge; thus, neonates may present
with decreased LV function, or even shock. In this
group, prognosis and recovery of cardiac function are
excellent after control of supraventricular tachy-
cardia. This is in contrast to the more incessant
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and recovery less rapid.
Etiologically, sustained rapid rates, QRS duration,
AV dyssynchrony, and heart rate irregularity all could
contribute to AIC, yet not all children with incessant
tachycardia develop AIC. In children, the tachycar-
dias most often associated with AIC have a narrow
QRS complex and 1:1 AV conduction. Heart rate
irregularity occurs in pediatric AIC as salvos of
tachycardia interspersed with periods of sinus
rhythm, rather than as the persistent heart rate ir-
regularity seen in AF.
As evident in many cardiac conditions, genetic
factors may underlie the development of AIC. Serum-
and glucocorticoid-regulated kinase 1 (SGK1), a
component of the cardiac phosphatidylinositol 3-
kinase signaling pathway has proarrhythmic effects
and has been linked to biochemical and functional
changes in the cardiac Naþ channel. These effects are
reversed by treatment with ranolazine, which blocks
the late Naþ current (91). Conversely, inhibition of
SGK1 in the heart protects against ﬁbrosis, HF, and
Naþ channel alterations after hemodynamic stress.
One might speculate that an underlying cardio-
myopathic process is unmasked by a tachyarrhythmia
or that genetic factors are responsible for both
arrhythmic and myopathic outcomes. Recent advan-
cement in our understanding of channelopathic
conditions and the overlapping of arrhythmic and
myopathic phenotypes seen in some patients lends
credibility to this theory (92–95). Mutations in the
cardiac Naþ channel and in the ryanodine receptor,
long known to be involved in arrhythmogenesis,
can now be linked to abnormalities of contractile
function (92).
PEDIATRIC ARRHYTHMIAS ASSOCIATED WITH AIC.
Atr ia l ectop ic tachycard ia . AET is the most com-
mon arrhythmia associated with AIC in children (96).
Although P-wave morphology and axis usually differ
from sinus rhythm, AET foci near the sinus node are
hard to differentiate from sinus tachycardia, espe-
cially in patients with HF, when tachycardia is ex-
pected. Increased automaticity is the most likely
mechanism; others include triggered activity and
micro-reentry (97–100). AET usually occurs without
structural heart disease but has been described after
congenital heart disease surgery (100) and in the
setting of channelopathies (101).
In a multicenter study of 249 children with AET,
28% had AIC (7). The cardiomyopathy varied from
asymptomatic mild LV dysfunction to the need for
HF medications in 52%; 3 required extracorporeal
membrane oxygenation (7). Multiple antiarrhythmic
medications or combinations of medications wereused, with beta-blockers being the most common
ﬁrst-line therapy. No trends emerged to deﬁne the
most successful medication. Catheter ablation was
effective in 81% of patients in whom it was used.
The use of electroanatomic mapping for ablation
improved success (102) and decreased recurrence
(103).
Spontaneous resolution of AET can occur, espe-
cially in those presenting within the ﬁrst year of life,
where 74% had resolution (7). Ablation proved safe
and effective, but the investigators suggested a trial
of medical therapy in the youngest patients, in whom
ablation may have more risk (104,105) and when
spontaneous resolution is more likely.
Permanent junctional reciprocating tachycardia. PJRT
is an accessory pathway–mediated tachycardia with a
long RP interval that occurs predominantly in infants
and children. The pathway can be located anywhere
in the AV junction but is usually posteroseptal (106).
Pathways are tortuous and slow conducting; thus,
tachycardia is often incessant.
In a recent review, 27% of patients with PJRT pre-
sented in fetal life, 7% with hydrops, a fetal mani-
festation of AIC (107). Isolation of the AV junction is a
continuing process that may not be complete at birth,
and the presence of accessory connections crossing
the annulus ﬁbrosis could result in persistent peri-
natal supraventricular tachycardia. Although most
children with PJRT present with palpitations or are
noted to have rapid heart rates, 18% presented with
AIC in a series of 194 children (107). Cardiomyopathy
is more likely to occur in children with longer RP
interval/cycle length ratios, consistent with an acces-
sory pathway with slow retrograde conduction and a
wide, excitable gap (108). PJRT is often incessant, and
those with incessant PJRT had longer RP intervals,
were younger at diagnosis, and more often had AIC
(107). The clinical course of PJRT is not benign, and
spontaneous resolution is unlikely (107).
A number of antiarrhythmic medications are used,
but a single most effective agent has not emerged
(107). Beta-blockers are the common ﬁrst choice,
likely reﬂecting physician comfort, rather than
proven efﬁcacy. Complete tachycardia suppression
with medications varies from 25% in the recent series
(107) to >80% in a study using regimens that included
amiodarone (109). Medical therapy is commonly used
in neonates and infants, whereas older children
undergo ablation. Catheter ablation is the primary
treatment for PJRT, with reported success rates
of 90% (107). Thus, the role for medical therapy is
limited to the neonate and small infant as a tempo-
rary measure to allow for the rare patient with spon-
taneous resolution, to suppress the tachycardia, and
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undertaking catheter ablation.
Junctional ectopic tachycardia. Junctional ectopic
tachycardia (JET), most commonly seen in small
children following congenital heart surgery (110), is
due to abnormal automaticity in the region of the AV
junction. JET unassociated with cardiac surgery can
present at any age, and congenital JET, presenting in
infancy, is associated with high morbidity and mor-
tality (110–112). In an early study, mortality was 34%,
with sudden death occurring in infants (113). In
a multicenter study of nonoperative JET, overall
mortality was low, with all deaths occurring in
children #6 months of age (114). Although only 16%
presented with HF, the tachycardia was incessant in
>40%. JET can be incessant or paroxysmal, although
infants <6 months of age are more likely to have
incessant tachycardia.
Medical management is commonly undertaken
(89%) as the ﬁrst step but was variably effective, with
a variety of drugs used. Beta-blockers were the most
common ﬁrst-line agent, but the majority required $2
drugs for control, with complete suppression seen in
only 11%. Amiodarone alone or in combination was
cited as the most effective for rate or rhythm control.
Catheter ablation for JET can be accomplished with
the preservation of AV nodal conduction (115,116),
and cryoablation has been associated with success
rates similar to those of radiofrequency ablation but
without AV block (114,117).
Ventr i cu la r tachycard ia and PVCs . Although rare
in children, ventricular tachycardia can result in AIC.
Incessant ventricular tachycardia of infancy occurs in
association with ventricular Purkinje cell tumors or
histiocytoid or lymphocytoid tumors (118–121). Both
left and right ventricular tachycardias can result in
pediatric AIC (86), and there are reports of PVC-
induced AIC in children (122,123). The burden of
ectopy needed, or other features associated with AIC
risk, have not been deﬁned.
AIC IN CHILDREN—SUMMARY. Tachyarrhythmias re-
sulting in AIC in children differ from those in the
adult. There is a predictable pattern of resolution
with treatment, and although previous small reports
have described weeks to months for functional re-
covery and years for reverse remodeling, the median
time to recovery in a larger study was <2 months (86).
Recovery seems independent of treatment strategy
(ablation vs. medical therapy). Recovery is predict-
able following arrhythmia control, and failure of re-
covery should instigate a search for factors, such as
subclinical arrhythmia recurrence or an underlying
cardiomyopathy.RECOVERY, PROGNOSIS, AND IMPACT OF
RECURRENT ARRHYTHMIA ON AIC
Clinical and animal studies have documented the
resolution of signs and symptoms of HF and recovery
of LV dysfunction with termination of culprit
arrhythmia. In several large animal models of pacing-
induced cardiomyopathy, cessation of pacing resul-
ted in signiﬁcant improvements in LV function and a
relative normalization of neurohormonal systems
(13,32,36,124,125). For example, LV volumes and sys-
tolic performance progress toward normalcy and
biomarker measurements of renin-angiotensin acti-
vation fall sharply by 7 to 14 days following cessation
of rapid pacing. Clinically, studies have shown that
recovery from AIC usually happens over weeks to
several months following arrhythmia suppression
(1,9,52,83).
In 75 patients with PVC-mediated cardiomyopathy
with successful catheter ablation, LVEF normalized in
5  6 months, with 68% recovering by 4 months (9). A
similar time course to recovery of LVEF was seen in
another study of 24 patients with AIC (predominantly
from AT) (1). Elimination of PVCs in patients with AIC
resulted in progressive improvement in LVEF and
clinical proﬁle, irrespective of underlying structural
heart disease (82).
Although AIC was originally considered a com-
pletely reversible form of cardiomyopathy, several
observations have cast doubt on whether the im-
provement in LVEF in AIC really means “cure.”
Whether myocardial structure and function fully
normalize remains unresolved. Resolution of HF and
recovery of LVEF may not imply normalization of LV
structure and function. Identifying predictors of re-
covery has therefore been of great interest. Early
improvement (>25% improvement in 1 week) of
LVEF following catheter ablation was predictive of
complete normalization in LVEF during long-term
follow-up (126). In a study of 69 patients with AIC
from outﬂow tract PVCs, signiﬁcant PVC suppression
(>80% reduction in PVC burden and always <5,000
PVCs/day) showed LVEF improvement comparable
to complete elimination (72). Long-standing and
persistent AIC prior to recognition and curative ther-
apy of the culprit arrhythmia could result in irrevers-
ible adverse LV remodeling and can limit complete
recovery (83). Another major factor affecting recovery
and outcomes is the effect of recurrent arrhythmia. In
a study of 24 patients with AIC and New York
Heart Association functional class III/IV HF, the me-
dian time from onset of arrhythmia to cardiomyopathy
and development of HF was 4.2 years. As one would
Gopinathannair et al. J A C C V O L . 6 6 , N O . 1 5 , 2 0 1 5
Arrhythmia-Induced Cardiomyopathy O C T O B E R 1 3 , 2 0 1 5 : 1 7 1 4 – 2 8
1724expect, aggressive rate and/or rhythm control of
the culprit arrhythmia resulted in signiﬁcant im-
provement in LVEF and resolution of HF in all patients
within 6 months. Five of 24 patients developed
recurrent arrhythmia, and all had a rapid decline in
LVEF (within 6 months of arrhythmia recurrence) with
recurrence of HF, which was again reversed with
aggressive arrhythmia control.
In 69 patients with AF and LVEF <40% who un-
derwent catheter ablation, those who maintained si-
nus rhythm (65%) had complete recovery of LVEF and
maintained normal LVEF after 28  11 months of
follow-up, compared with those who had recurrent
AF/AT. Interestingly, recovery of LVEF at 6 months
was similar in both groups, but further improvement
was seen only in the sinus rhythm group (40). An
example of a patient with recurrent AF and AIC is
shown in Table 2, where the time course of LVEF
changes in relation to recurrence of AF is apparent.
These data demonstrate that AIC is reversible if the
culprit arrhythmia is controlled, but recurrence of the
arrhythmia can result in HF and an abrupt decline in
LVEF (1).
In patients with AIC who have had resolution of
arrhythmia, echocardiographic evaluations noted
persistently elevated stroke volumes and LV end-
systolic and end-diastolic volume indexes, suggest-
ing persistent negative remodeling (127). In patients
with AIC from focal AT who had normalization ofTABLE 2 An Example of the Clinical Course of AIC When the
Culprit Arrhythmia Was Not Eliminated: A 54-Year-Old Man With
AF and LVEF of 30%
Time,
Months LVEF, % Intervention
0 30 Diuretics, ACE inhibitors, TEE, cardioversion
1 47
6 52 AIC diagnosed
14 — Recurrent AF per patient; did not see a doctor
18 25 Cardioverted; started taking sotalol but
discontinued due to increased QTc
interval; amiodarone started
23 50
35 20 Admitted with heart failure; recurrent AF
with rapid rates; underwent AF ablation;
amiodarone continued
40 55
43 40 LAﬂutterwithventricular rateof110beats/min;
underwent perimitral LA ﬂutter ablation
53 52
63 53 Sinus rhythm; taking amiodarone (200 mg
daily), beta-blockers, ACE inhibitor,
warfarin
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial ﬁbrillation; AIC ¼ arrhythmia-
induced cardiomyopathy; LA ¼ left atrial; LVEF ¼ left ventricular ejection fraction;
TEE ¼ transesophageal echocardiography.LVEF with successful ablation, CMR scanning 5 years
after ablation showed higher LV end-diastolic vol-
umes and evidence for diffuse ﬁbrosis compared with
patients with focal AT without AIC and with healthy
controls (128).
Current evidence thus suggests that myocardial
structural and functional impairment can persist in
patients with AIC, even after successful elimination
of the causal arrhythmia and normalization of LVEF
and symptoms, suggesting that recovery is incom-
plete at an ultrastructural level. The “recovery” from
AIC perhaps represents a transition to another form of
LV remodeling and dysfunction. The mechanisms
underlying these abnormalities, and whether pat-
terns of recovery from AIC differ among different
arrhythmias, require further study.
RISK OF SUDDEN DEATH
Long-term survival of patients with AIC following
arrhythmia resolution is likely; however, concerns
remain. Sudden cardiac death has been reported in
patients with AIC following symptom recovery and
LVEF normalization (1,6,129). Nerheim et al. (1) re-
ported 3 patients with AF-mediated AIC who died
suddenly during follow-up while asymptomatic and
having preserved LVEF and good functional status.
Two patients were on adequate rate control and the
third was on rhythm control. All 3 had index LVEFs
that were markedly lower than those in the rest of
the study group (n ¼ 24), suggesting a greater risk
in patients with severe baseline LV dysfunction (1).
Available reports thus have suggested that certain
patients with AIC could be at risk for sudden car-
diac death, despite normalization of LVEF. Howev-
er, the true risk of sudden death in patients with
AIC, especially following arrhythmia suppression
and LVEF recovery, is likely low, and there is no
present justiﬁcation for implantable cardioverter-
deﬁbrillator (ICD) insertion in patients with revers-
ible cardiomyopathy (on the basis of improvement
in LVEF).
Close surveillance, as well as continuation of
neurohormonal antagonists to aid positive remodel-
ing, is warranted in AIC, even after arrhythmia sup-
pression and normalization of LVEF. A follow-up CMR
for assessment of residual ﬁbrosis/scar could provide
valuable prognostic information (128). Arrhythmia
recurrence can be devastating (1,6,129).
FUTURE DIRECTIONS
Since the original observations by Philips and Levine
in 1949 of the association between rapid AF and
a reversible form of HF (130), AIC has become a
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investigations have shed light on the etiology,
pathophysiology, clinical features, treatment, and
prognosis of AIC. However, several gaps in our un-
derstanding still exist. The true incidence and prev-
alence of AIC need to be deﬁned. Future research
should focus on speciﬁc pathophysiological mecha-
nisms for cardiomyopathy in relation to a particular
arrhythmia. Identifying clinical, genetic, and de-
mographic characteristics that predispose a particular
individual to AIC in the setting of a culprit arrhythmia
will be crucial for early recognition of this disease
process, before cardiomyopathy develops. Questions
still exist concerning optimal therapeutic strategies:
Is rhythm control really better than rate control for
improving long-term outcomes in AF-mediated AIC?
How can we best prevent residual ultrastructural ab-
normalities? What are the interrelationships between
structural heart disease, arrhythmia, and risk of
sudden death?
THE “BIG PICTURE”: CLINICAL AND
GLOBAL HEALTH IMPACT OF AIC
Heart failure is increasing globally. Tachyarrhythmias
and frequent PVCs remain an important cause of
nonischemic cardiomyopathy and manifest HF that
is partially or completely reversible with control of
the arrhythmia. However, this condition remains
under-recognized, often leading to worsening HF
and deterioration of LV function. Given that limitedtherapeutic options exist for patients with advanced
HF, the ability to detect a potentially reversible cause
is critical. Raising awareness about this condition
globally is paramount.
CONCLUSIONS
AIC can affect patients of any age and has a wide
range of clinical manifestations, from asymptomatic
tachycardia or ectopy to cardiomyopathy to end-
stage HF. Early recognition is critical, and aggres-
sive treatment aimed at controlling or eliminating
the inciting arrhythmia results in symptom resolu-
tion and recovery of ventricular function. However,
cellular and extracellular ultrastructural changes
can persist and can contribute to a rapid decline in
cardiac function with arrhythmia recurrence, as well
as confer a risk of sudden cardiac death. Thus,
this supposedly “benign” and “reversible” condition
poses unique challenges to the practicing cardiolo-
gist. Novel approaches for early detection, as well
as targeted intervention, are warranted and may
ultimately improve long-term outcomes for these
patients.
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